2024
Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma
Husain Z, Rybkin A, Lee V, Young M, Eskander A, Burtness B, Park H. Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e759-e760. DOI: 10.1016/j.ijrobp.2024.07.1668.Peer-Reviewed Original ResearchLymphovascular space invasionOral cavity carcinomaOverall survivalIntermediate-riskHigh riskT3/4 diseaseDistant metastasisN stageStandard riskPrediction of distant metastasisGrade 3 tumorsMedian follow-upNational Cancer DatabasePathological risk factorsOral cavity cancerKaplan-Meier methodLog-rank testSubsets of patientsHospital-based cohortClinical trial stratificationHigh-volume hospitalsT3/4 tumorsMedian followSurgical resectionIndividualized treatment selection
2021
Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study
Xiao C, Beitler JJ, Peng G, Levine ME, Conneely KN, Zhao H, Felger JC, Wommack EC, Chico CE, Jeon S, Higgins KA, Shin DM, Saba NF, Burtness BA, Bruner DW, Miller AH. Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study. Cancer 2021, 127: 3361-3371. PMID: 34027995, DOI: 10.1002/cncr.33641.Peer-Reviewed Original ResearchConceptsC-reactive proteinIL-6 levelsEpigenetic age accelerationNeck cancerInterleukin-6Inflammatory markersHigher epigenetic age accelerationLower C-reactive proteinAge accelerationHigher C-reactive proteinMultidimensional Fatigue Inventory-20Poor functional outcomeBlood DNA methylationMonths postradiotherapyAdvanced diseaseConcurrent chemoradiationMost patientsDistant metastasisFunctional outcomeSevere fatigueTreatment completionRadiation therapyPatientsGreater fatigueInflammationAssociation of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer
Xiao C, Miller AH, Peng G, Levine ME, Conneely KN, Zhao H, Eldridge RC, Wommack EC, Jeon S, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Irwin ML, Ferrucci LM, Ulrich B, Qian DC, Beitler JJ, Bruner DW. Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 157-167. PMID: 33882281, PMCID: PMC8802868, DOI: 10.1016/j.ijrobp.2021.04.002.Peer-Reviewed Original ResearchConceptsProgression-free survivalBody mass indexQuality of lifeHigher epigenetic age accelerationTreatment-related symptomsOverall survivalEpigenetic age accelerationRadiation therapyRisk factorsClinical characteristicsNeck cancerAge accelerationWorse overall survivalHuman papilloma virusFaster biological agingAdverse eventsDistant metastasisLifestyle factorsMass indexCancer outcomesBlood biomarkersPapilloma virusFunctional assessmentHigher HRPatientsMeta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Laskar SG, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zakotnik B, Sharma A, Bensadoun RJ, Redda M, Racadot S, Fountzilas G, Brizel D, Rovea P, Argiris A, Nagy ZT, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P, Pignon JP, Group M, Adelstein D, Alfonsi M, Belkacemi Y, Bar-Ad V, Bernier J, Bratland Å, Calais G, Campbell B, Caudell J, Chabaud S, Chamorey E, Chaukar D, Choi K, Choussy O, Collette L, Cruz J, Dani C, Dauzier E, Forastiere A, Garaud P, Gregoire V, Hackshaw A, Haddad E, Haffty B, Hansen A, Hayoz S, Horiot J, Jeremic B, Karrison T, Langendijk J, Lapeyre M, Lartigau E, Leong T, Le Q, Lee P, Lewin F, Lin A, Lopes A, Mehta S, Moon J, Moyal E, Occéan B, Olmi P, Orecchia R, O'Sullivan B, Overgaard J, Petit C, Quon H, Sanguineti G, Satar T, Simes J, Simon C, Sire C, Staar S, Stromberger C, Strojan P, Temam S, Thomson D, Timochenko A, Torri V, Tseroni V, Vermorken J, Vokes E, Waldron J, Wernecke K, Widder J, Zackrisson B. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy And Oncology 2021, 156: 281-293. PMID: 33515668, PMCID: PMC8386522, DOI: 10.1016/j.radonc.2021.01.013.Peer-Reviewed Original ResearchConceptsLoco-regional treatmentConcomitant CTConcomitant chemotherapyOverall survivalNeck cancerNon-metastatic headPoor performance statusSquamous cell headIndividual patient dataNon-metastatic carcinomasAddition of inductionFixed-effects modelPerformance statusPatient ageDistant metastasisRandomized trialsMain endpointCell headStage IIIMeta-AnalysisPatientsChemotherapyPatient dataTrialsCancer
2020
Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell Carcinoma
Haider SP, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, Kann BH, Judson BL, Prasad ML, Burtness B, Mahajan A, Payabvash S. Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell Carcinoma. Cancers 2020, 12: 1778. PMID: 32635216, PMCID: PMC7407414, DOI: 10.3390/cancers12071778.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaProgression-free survivalPositron emission tomographySquamous cell carcinomaOverall survivalC-indexRisk stratificationCell carcinomaSurvival prognosticationHPV-negative oropharyngeal squamous cell carcinomaPre-treatment PET/CTMetastatic cervical lymph nodesBaseline positron emission tomographyBaseline distant metastasesCervical lymph nodesHuman papillomavirus (HPV) statusAmerican Joint CommitteeKaplan-Meier analysisPET/CT RadiomicsHarrell's C-indexAverage C-indexPET/CTRadiomics imaging featuresCurative intentDistant metastasis
2018
Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma
Lee NCJ, Kelly JR, Park HS, An Y, Judson BL, Burtness BA, Husain ZA. Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. Oral Oncology 2018, 85: 35-39. PMID: 30220317, DOI: 10.1016/j.oraloncology.2018.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCarcinoma, Squamous CellCombined Modality TherapyFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeck DissectionNeoplasm MetastasisNeoplasm Recurrence, LocalOropharyngeal NeoplasmsPapillomavirus InfectionsProgression-Free SurvivalProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSalvage TherapyConceptsProgression-free survivalInvolved lymph nodesDistant metastasisPatterns of failureLocoregional recurrenceLymph nodesHuman papillomavirus-positive oropharyngeal carcinomaMultivariate analysisEdition American Joint CommitteeRate of DMWorse progression-free survivalHigh DM rateDedicated clinical trialsAmerican Joint CommitteeCancer (AJCC) staging systemProportional hazards regressionExternal beam radiationOropharynx cancerFree survivalNeck dissectionOropharyngeal carcinomaOverall survivalDisease recurrenceIntraoperative brachytherapyOPC patients
2016
Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base
Kuo P, Sosa JA, Burtness BA, Husain ZA, Mehra S, Roman SA, Yarbrough WG, Judson BL. Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base. Cancer 2016, 122: 1853-1860. PMID: 27019213, DOI: 10.1002/cncr.29962.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCarcinoma, Squamous CellChemoradiotherapy, AdjuvantDatabases, FactualFemaleHead and Neck NeoplasmsHumansHypopharyngeal NeoplasmsKaplan-Meier EstimateMaleMiddle AgedProportional Hazards ModelsRadiotherapy, AdjuvantSquamous Cell Carcinoma of Head and NeckUnited StatesYoung AdultConceptsHypopharyngeal cancerDefinitive settingTreatment modalitiesSurvival rateNational Cancer Data BaseMultivariate Cox regression analysisKaplan-Meier survival curvesPrimary hypopharyngeal cancerUse of chemotherapyCox regression analysisDefinitive chemoradiotherapyAdjuvant chemoradiotherapyAdjuvant treatmentDefinitive radiotherapyAdult patientsOverall survivalClinical factorsDefinitive treatmentImproved survivalDistant metastasisSurvival outcomesChemoradiotherapyRadiotherapySurvival analysisSurvival curves
2015
National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database
Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL. National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database. Cancer Medicine 2015, 4: 1828-1835. PMID: 26471244, PMCID: PMC5123708, DOI: 10.1002/cam4.546.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCombined Modality TherapyComorbidityDatabases, FactualFemaleHead and Neck NeoplasmsHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPopulation SurveillanceRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesYoung AdultConceptsNational Cancer DatabaseSystemic therapyPalliative therapyTreatment patternsNeck cancerCancer DatabaseClinical trialsMedicaid/uninsured statusCox proportional hazards analysisCommon treatment regimenNational treatment patternsCharlson comorbidity scorePrimary disease siteRetrospective cohort analysisProportional hazards analysisRisk of deathNeck cancer patientsMedicare/Comorbidity scoreMetastatic headOverall survivalSystemic treatmentTreatment regimenDistant metastasisKaplan-Meier
2010
SU‐GG‐T‐180: Intensity‐Modulated Radiation Therapy (IMRT) for the Para‐Nasal Sinus (PNS) Malignancies: Outcomes from Fox Chase Cancer Center (FCCC)
Turaka A, Cattaneo R, Nicos N, Lango M, Burtness B, Ridge J, Feigenberg S. SU‐GG‐T‐180: Intensity‐Modulated Radiation Therapy (IMRT) for the Para‐Nasal Sinus (PNS) Malignancies: Outcomes from Fox Chase Cancer Center (FCCC). Medical Physics 2010, 37: 3226-3226. DOI: 10.1118/1.3468570.Peer-Reviewed Original ResearchFox Chase Cancer CenterIntensity-modulated radiation therapySquamous cellsStage III/IV diseaseMedian age 68 yearsStage I/IILocoregional control rateAge 68 yearsOverall survival rateParanasal sinus tumorsBase of skullMedian followMedian doseLocal recurrenceMucosal melanomaSinus malignanciesClinical outcomesDistant metastasisNeck diseasePerineural invasionSinus tumorClinical stageHigher complicationsNegative marginsOptic apparatus
2007
Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology
Burtness B, Powell M, Berlin J, Liles D, Chapman A, Mitchell E, Benson A. Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology. Journal Of Clinical Oncology 2007, 25: 4519-4519. DOI: 10.1200/jco.2007.25.18_suppl.4519.Peer-Reviewed Original ResearchPhase II trialArm AII trialPS 0Arm BPancreatic cancerMedian survivalOverall survivalRandomized phase II trialECOG PS 0Treatment-related deathsMedian overall survivalMetastatic pancreatic cancerTherapeutic anticoagulationDocetaxel chemotherapyMetastatic patientsPrimary endpointBiologic agentsDistant metastasisHistologic confirmationNormal bilirubinSame therapyYear survivalMedian numberArm 2
2005
Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation
Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA. Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation. International Journal Of Surgical Pathology 2005, 13: 319-327. PMID: 16273187, DOI: 10.1177/106689690501300403.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBone NeoplasmsBreast NeoplasmsCarcinoma, AdenosquamousCarcinoma, Squamous CellCarcinosarcomaCell DifferentiationErbB ReceptorsFollow-Up StudiesHumansImmunohistochemistryKeratinsLung NeoplasmsLymph NodesLymphatic MetastasisMiddle AgedNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenConceptsEpidermal growth factor receptorDisease-free survivalSquamous differentiationBreast carcinomaEstrogen receptorLymph nodesHER2 statusTissue microarrayEGFR expressionFull axillary lymph node dissectionAxillary lymph node dissectionLymph node positive breast carcinomaNode-positive breast carcinomaHuman epidermal growth factor receptorEGFR-negative tumorsLymph node dissectionPositive lymph nodesLymph node statusPositive breast carcinomaEGFR-positive tumorsEGFR-positive tumor cellsGrowth factor receptorNode dissectionEGFR positivityDistant metastasis
1999
Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting.
Burtness B, Windsor S, Holston B, DiStasio S, Staugaard-Hahn C, Abrantes J, Kneuper-Hall R, Farber L, Orell J, Bober-Sorcinelli K, Haffty BG, Reiss M. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. The Cancer Journal 1999, 5: 224-9. PMID: 10439168.Peer-Reviewed Original ResearchConceptsBreast cancerDefinitive breast cancer surgeryMetastatic axillary lymph nodesHigh-risk breast cancerMore axillary nodesMyalgia/arthralgiaGrade 3 toxicityNausea/vomitingPercent of patientsAxillary lymph nodesHigh-risk patientsBreast cancer surgeryPreliminary efficacy dataFilgrastim supportNeutropenic feverAcceptable toxicityAdjuvant therapyAxillary nodesDose intensityStandard therapyBone scanLymph nodesCancer surgeryDistant metastasisAcute leukemia